DK0708656T3 - Antigene LHRH peptidkonstruktioner og universelle syntetiske immunstimulatorer til vacciner - Google Patents

Antigene LHRH peptidkonstruktioner og universelle syntetiske immunstimulatorer til vacciner

Info

Publication number: DK0708656T3
Authority: DK; Denmark
Prior art keywords: peptides; lhrh; peptide; helper; cell epitope
Prior art date: 1993-04-27

Application number

DK94915447T

Other languages

English (en)

Inventor

Anna E Ladd

Timothy Zamb

Chang Yi Wang

Original Assignee

United Biomedical Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-04-27

Filing date

1994-04-28

Publication date

2002-12-02

1994-04-28 Application filed by United Biomedical Inc filed Critical United Biomedical Inc

2002-12-02 Application granted granted Critical

2002-12-02 Publication of DK0708656T3 publication Critical patent/DK0708656T3/da

Links

108090000765 processed proteins & peptides Proteins 0.000 title abstract 14
101000904173 Homo sapiens Progonadoliberin-1 Proteins 0.000 title 1
102100024028 Progonadoliberin-1 Human genes 0.000 title 1
101000996723 Sus scrofa Gonadotropin-releasing hormone receptor Proteins 0.000 title 1
230000000890 antigenic effect Effects 0.000 title 1
XLXSAKCOAKORKW-UHFFFAOYSA-N gonadorelin Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 XLXSAKCOAKORKW-UHFFFAOYSA-N 0.000 title 1
229960005486 vaccine Drugs 0.000 title 1
102000004196 processed proteins & peptides Human genes 0.000 abstract 10
108700012941 GNRH1 Proteins 0.000 abstract 6
239000000579 Gonadotropin-Releasing Hormone Substances 0.000 abstract 6
230000001419 dependent effect Effects 0.000 abstract 3
210000002443 helper t lymphocyte Anatomy 0.000 abstract 3
201000009030 Carcinoma Diseases 0.000 abstract 2
101710198693 Invasin Proteins 0.000 abstract 2
MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 abstract 2
239000003098 androgen Substances 0.000 abstract 2
230000002163 immunogen Effects 0.000 abstract 2
206010003694 Atrophy Diseases 0.000 abstract 1
206010004446 Benign prostatic hyperplasia Diseases 0.000 abstract 1
206010006187 Breast cancer Diseases 0.000 abstract 1
208000026310 Breast neoplasm Diseases 0.000 abstract 1
241000606161 Chlamydia Species 0.000 abstract 1
201000009273 Endometriosis Diseases 0.000 abstract 1
102400000921 Gastrin Human genes 0.000 abstract 1
102000004862 Gastrin releasing peptide Human genes 0.000 abstract 1
108090001053 Gastrin releasing peptide Proteins 0.000 abstract 1
108010052343 Gastrins Proteins 0.000 abstract 1
102000036770 Islet Amyloid Polypeptide Human genes 0.000 abstract 1
108010041872 Islet Amyloid Polypeptide Proteins 0.000 abstract 1
101710105759 Major outer membrane porin Proteins 0.000 abstract 1
101710164702 Major outer membrane protein Proteins 0.000 abstract 1
241000224017 Plasmodium berghei Species 0.000 abstract 1
206010036618 Premenstrual syndrome Diseases 0.000 abstract 1
206010060862 Prostate cancer Diseases 0.000 abstract 1
208000004403 Prostatic Hyperplasia Diseases 0.000 abstract 1
241000700159 Rattus Species 0.000 abstract 1
230000037444 atrophy Effects 0.000 abstract 1
AOXOCDRNSPFDPE-UKEONUMOSA-N chembl413654 Chemical compound C([C@H](C(=O)NCC(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](C)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@@H](N)CCC(O)=O)C1=CC=C(O)C=C1 AOXOCDRNSPFDPE-UKEONUMOSA-N 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
230000000694 effects Effects 0.000 abstract 1
229940011871 estrogen Drugs 0.000 abstract 1
239000000262 estrogen Substances 0.000 abstract 1
PUBCCFNQJQKCNC-XKNFJVFFSA-N gastrin-releasingpeptide Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)CNC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)C(C)C)[C@@H](C)O)C(C)C)[C@@H](C)O)C(C)C)C1=CNC=N1 PUBCCFNQJQKCNC-XKNFJVFFSA-N 0.000 abstract 1
230000028993 immune response Effects 0.000 abstract 1
230000036039 immunity Effects 0.000 abstract 1
230000001939 inductive effect Effects 0.000 abstract 1
208000000509 infertility Diseases 0.000 abstract 1
230000036512 infertility Effects 0.000 abstract 1
231100000535 infertility Toxicity 0.000 abstract 1
210000000056 organ Anatomy 0.000 abstract 1
208000025661 ovarian cyst Diseases 0.000 abstract 1
230000002265 prevention Effects 0.000 abstract 1
230000001681 protective effect Effects 0.000 abstract 1
230000000306 recurrent effect Effects 0.000 abstract 1
210000002966 serum Anatomy 0.000 abstract 1
230000004936 stimulating effect Effects 0.000 abstract 1
230000001629 suppression Effects 0.000 abstract 1
230000002381 testicular Effects 0.000 abstract 1
229960003604 testosterone Drugs 0.000 abstract 1
201000007331 uterine benign neoplasm Diseases 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0006—Contraceptive vaccins; Vaccines against sex hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/16—Masculine contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/235—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bordetella (G)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
- C07K14/245—Escherichia (G)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/295—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Chlamydiales (O)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/34—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Corynebacterium (G)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
- C07K14/445—Plasmodium
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/57572—Gastrin releasing peptide
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/595—Gastrins; Cholecystokinins [CCK]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/23—Luteinising hormone-releasing hormone [LHRH]; Related peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18711—Rubulavirus, e.g. mumps virus, parainfluenza 2,4
- C12N2760/18722—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Gastroenterology & Hepatology (AREA)
Engineering & Computer Science (AREA)
Endocrinology (AREA)
Bioinformatics & Cheminformatics (AREA)
Diabetes (AREA)
Toxicology (AREA)
Virology (AREA)
Immunology (AREA)
Zoology (AREA)
Reproductive Health (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Tropical Medicine & Parasitology (AREA)
Obesity (AREA)
Microbiology (AREA)
Hematology (AREA)
Emergency Medicine (AREA)
Epidemiology (AREA)
Mycology (AREA)
Gynecology & Obstetrics (AREA)
Urology & Nephrology (AREA)
AIDS & HIV (AREA)

DK94915447T 1993-04-27 1994-04-28 Antigene LHRH peptidkonstruktioner og universelle syntetiske immunstimulatorer til vacciner DK0708656T3 (da)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US5716693A	1993-04-27	1993-04-27
US22927594A	1994-04-14	1994-04-14
PCT/US1994/004832 WO1994025060A1 (en)	1993-04-27	1994-04-28	Immunogenic lhrh peptide constructs and synthetic universal immune stimulators for vaccines

Publications (1)

Publication Number	Publication Date
DK0708656T3 true DK0708656T3 (da)	2002-12-02

Family

ID=26736147

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK94915447T DK0708656T3 (da)	1993-04-27	1994-04-28	Antigene LHRH peptidkonstruktioner og universelle syntetiske immunstimulatorer til vacciner

Country Status (11)

Country	Link
EP (1)	EP0708656B1 (da)
JP (2)	JP3795914B2 (da)
AT (1)	ATE221387T1 (da)
AU (1)	AU687805B2 (da)
CA (1)	CA2161445C (da)
DE (1)	DE69431114T2 (da)
DK (1)	DK0708656T3 (da)
ES (1)	ES2180576T3 (da)
FI (1)	FI955101A (da)
NO (1)	NO316121B1 (da)
WO (1)	WO1994025060A1 (da)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6607727B1 (en)	1991-08-26	2003-08-19	The Scripps Research Institute	Peptides for inducing cytotoxic T lymphocyte responses to hepatitus B virus
US6235288B1 (en)	1992-08-26	2001-05-22	The Scripps Research Institute	Peptides for inducing cytotoxic T lymphocyte responses to hepatitis B virus
JP3657603B2 (ja) *	1993-02-26	2005-06-08	ザスクリップスリサーチインスティテュート	Ｂ型肝炎のウイルスに対する細胞障害性ｔリンパ球の応答を誘発するペプチド
US5688506A (en) *	1994-01-27	1997-11-18	Aphton Corp.	Immunogens against gonadotropin releasing hormone
CA2186595A1 (en) *	1994-03-28	1995-10-05	Chang Yi Wang	Synthetic peptide based immunogens for the treatment of allergy
US6410022B1 (en)	1995-05-01	2002-06-25	Avant Immunotherapeutics, Inc.	Modulation of cholesteryl ester transfer protein (CETP) activity
JP3910635B2 (ja)	1995-06-06	2007-04-25	アバントイミュノーセラピューティクス，インコーポレイテッド	Ｈｄｌコレステロールレベルを増大する方法
US5843462A (en)	1995-11-30	1998-12-01	Regents Of The University Of Minnesota	Diphtheria toxin epitopes
US6610297B1 (en)	1996-03-01	2003-08-26	Novartis Ag	Peptide immunogens for vaccination against and treatment of allergy
JP2000509270A (ja) *	1996-04-19	2000-07-25	ヘンリーエム．ジャクソンファンデーションフォーザアドバンスメントオブミリタリーメディシン	ヒスチジンタグ付きインチミン、ならびに免疫応答を刺激し、標的能力を有する抗原担体としてインチミンを使用する方法
EP0895543B1 (en)	1996-04-19	2006-06-28	Henry M. Jackson Foundation For The Advancement Of Military Medicine	Method of stimulating an immune response by administration of host organisms that express intimin alone or as a fusion protein with one or more other antigens
US6284533B1 (en)	1996-05-01	2001-09-04	Avant Immunotherapeutics, Inc.	Plasmid-based vaccine for treating atherosclerosis
US6846808B1 (en)	1996-05-01	2005-01-25	Avant Immunotherapeutics, Inc.	Plasmid-based vaccine for treating atherosclerosis
US6309646B1 (en)	1996-05-09	2001-10-30	The Henry M. Jackson Foundation For The Advancement Of Military Medicine	Protein-polysaccharide conjugate vaccines and other immunological reagents prepared using homobifunctional and heterobifunctional vinylsulfones, and processes for preparing the conjugates
EP0912195B1 (en) *	1996-06-25	2009-01-21	Pepscan Systems B.V.	Vaccine comprising antigens bound to carriers through labile bonds
JP5132851B2 (ja) *	1997-08-05	2013-01-30	フラームス・インテルウニフェルシタイル・インステイチュート・フォール・ビオテヒノロヒー・ヴェーゼットウェー（ヴェーイーベー・ヴェーゼットウェー）	新しい免疫防御性インフルエンザ抗原及びそのワクチン接種への使用
CA2315537A1 (en)	1997-12-16	1999-06-24	Regents Of The University Of Minnesota	Methods to treat undesirable immune responses
US6090388A (en) *	1998-06-20	2000-07-18	United Biomedical Inc.	Peptide composition for prevention and treatment of HIV infection and immune disorders
TWI227241B (en)	1998-06-20	2005-02-01	United Biomedical Inc	IgE-CH3 domain antigen peptide, peptide conjugate containing the same, and pharmaceutical composition for treating allergies containing the peptide conjugate
US6107021A (en) *	1998-06-20	2000-08-22	United Biomedical, Inc.	Synthetic peptide vaccines for foot-and-mouth disease
US6025468A (en) *	1998-06-20	2000-02-15	United Biomedical, Inc.	Artificial T helper cell epitopes as immune stimulators for synthetic peptide immunogens including immunogenic LHRH peptides
WO2000032626A1 (en) *	1998-11-25	2000-06-08	Regents Of The University Of Minnesota	Methods of using epitope peptides of human pathogens
UA81216C2 (en) *	1999-06-01	2007-12-25		Prevention and treatment of amyloid disease
JP2003532740A (ja)	2000-05-05	2003-11-05	アフトンコーポレーション	キメラペプチド免疫原
US6780969B2 (en) *	2000-12-22	2004-08-24	United Biomedical, Inc.	Synthetic peptide composition as immunogens for prevention of urinary tract infection
US6906169B2 (en) *	2001-05-25	2005-06-14	United Biomedical, Inc.	Immunogenic peptide composition comprising measles virus Fprotein Thelper cell epitope (MUFThl-16) and N-terminus of β-amyloid peptide
US8088388B2 (en) *	2002-02-14	2012-01-03	United Biomedical, Inc.	Stabilized synthetic immunogen delivery system
PL209696B1 (pl) *	2002-04-19	2011-10-31	Univ Toronto	Peptyd, kompozycja peptydowa, kompozycja immunogenna, zastosowania kompozycji immunogennej oraz sposób określania czy związek stanowi inhbitor odkładania się i tworzenia włókienek amyloidu
RU2361876C2 (ru)	2003-04-22	2009-07-20	Сосьете Де Консей Де Решерш Э Д`Аппликасьон Сьентифик С.А.С.	Пептидные векторы
KR20080004445A (ko) *	2004-09-10	2008-01-09	더 카운실 오브 더 퀸스랜드 인스티튜트 오브 메디칼 리서어치	절단형 ｌｈｒｈ 포뮬레이션
EP1885393A4 (en)	2005-05-18	2011-03-02	Childrens Hosp & Res Ct Oak	METHODS AND COMPOSITIONS FOR IMMUNIZATION AGAINST CHLAMYDIA INFECTIONS
CN101189026A (zh) *	2005-06-01	2008-05-28	辉瑞产品公司	用于治疗尿失禁的疫苗组合物及方法
CA2698968A1 (en) *	2007-09-11	2009-03-19	Mondobiotech Laboratories Ag	Use of a peptide as a therapeutic agent
JP4535174B2 (ja)	2008-07-11	2010-09-01	トヨタ自動車株式会社	車両の制御装置および制御方法
WO2014077825A1 (en)	2012-11-16	2014-05-22	United Biomedical, Inc.	Synthetic peptide-based emergency vaccine against foot and mouth disease (fmd)
CN107073086B (zh) *	2014-07-25	2021-07-27	美国联合生物医学公司	免疫性lhrh组合物及其在猪只中的应用
AU2018242156B2 (en) *	2017-03-30	2021-07-29	Progastrine Et Cancers S.À R.L.	Compositions and methods for detecting and treating prostate cancer using progastrin binding molecule
TW202144387A (zh) *	2020-02-11	2021-12-01	美商聯合生物醫學公司	針對胰島澱粉樣多肽（iapp）的胜肽免疫原及其預防和治療與聚集iapp相關疾病的製劑

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4613586A (en) *	1984-04-19	1986-09-23	Board Of Trustees Of The Leland Stanford Junior University	Gastrin releasing peptide-like peptides
US4608251A (en) *	1984-11-09	1986-08-26	Pitman-Moore, Inc.	LHRH analogues useful in stimulating anti-LHRH antibodies and vaccines containing such analogues
EP0301850A3 (en) *	1987-07-31	1990-10-31	Syntex (U.S.A.) Inc.	Lhrh antagonist analogs and 19-nor-progestational steroids for therapy
GB8812214D0 (en) *	1988-05-24	1988-06-29	Hoffmann La Roche	Use of peptide from circumsporozoite protein of p falciparum as universally recognized t-cell epitope
US5171835A (en) *	1988-10-21	1992-12-15	The Administrators Of The Tulane Educational Fund	LHRH antagonists
GB8913737D0 (en) *	1989-06-15	1989-08-02	Univ Birmingham	A novel anti-allergy treatment
GB8924438D0 (en) *	1989-10-31	1989-12-20	Hoffmann La Roche	Vaccine composition
IT1237764B (it) *	1989-11-10	1993-06-17	Eniricerche Spa	Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici.
CH683101A5 (de) *	1990-09-18	1994-01-14	Biotech Australia Pty Ltd	T-Zellen-Epitope.
WO1992020370A1 (en) *	1991-05-13	1992-11-26	Regents Of The University Of California	Liposomal polysaccharide vaccines
IL102964A0 (en) *	1991-08-26	1993-01-31	Cytel Corp	Hla-restricted hepatitis b virus ctl epitopes

1994
- 1994-04-28 AT AT94915447T patent/ATE221387T1/de active
- 1994-04-28 WO PCT/US1994/004832 patent/WO1994025060A1/en active IP Right Grant
- 1994-04-28 AU AU66702/94A patent/AU687805B2/en not_active Expired
- 1994-04-28 DE DE69431114T patent/DE69431114T2/de not_active Expired - Lifetime
- 1994-04-28 CA CA002161445A patent/CA2161445C/en not_active Expired - Lifetime
- 1994-04-28 DK DK94915447T patent/DK0708656T3/da active
- 1994-04-28 ES ES94915447T patent/ES2180576T3/es not_active Expired - Lifetime
- 1994-04-28 JP JP52461494A patent/JP3795914B2/ja not_active Expired - Lifetime
- 1994-04-28 EP EP94915447A patent/EP0708656B1/en not_active Expired - Lifetime
1995
- 1995-10-26 FI FI955101A patent/FI955101A/fi not_active Application Discontinuation
- 1995-10-26 NO NO19954279A patent/NO316121B1/no not_active IP Right Cessation
2004
- 2004-10-06 JP JP2004293637A patent/JP2005060406A/ja active Pending

Also Published As

Publication number	Publication date
ES2180576T3 (es)	2003-02-16
FI955101A (fi)	1995-12-21
EP0708656B1 (en)	2002-07-31
AU6670294A (en)	1994-11-21
EP0708656A4 (en)	1999-06-23
FI955101A0 (fi)	1995-10-26
EP0708656A1 (en)	1996-05-01
NO316121B1 (no)	2003-12-15
AU687805B2 (en)	1998-03-05
DE69431114T2 (de)	2003-03-13
CA2161445C (en)	2009-06-30
JP3795914B2 (ja)	2006-07-12
ATE221387T1 (de)	2002-08-15
JP2005060406A (ja)	2005-03-10
CA2161445A1 (en)	1994-11-10
JPH09503742A (ja)	1997-04-15
NO954279L (no)	1995-12-27
NO954279D0 (no)	1995-10-26
WO1994025060A1 (en)	1994-11-10
DE69431114D1 (de)	2002-09-05

Publication	Publication Date	Title
DK0708656T3 (da)	2002-12-02	Antigene LHRH peptidkonstruktioner og universelle syntetiske immunstimulatorer til vacciner
GR3031716T3 (en)	2000-02-29	Immunogens against gonadotropin releasing hormone
Thompson Jr	2000	Immunization against GnRH in male species (comparative aspects)
Alexander	1974	Escape from immune destruction by the host through shedding of surface antigens: is this a characteristic shared by malignant and embryonic cells?
HK1143950A1 (en)	2011-01-21	Artificial t helper cell epitopes as immune stimulators for synthetic peptide immunogens
NZ314058A (en)	2000-08-25	Use of ganglioside-KLH conjugate vaccines with QS-21 to treat cancer
ATE328091T1 (de)	2006-06-15	Oligoepitop-peptid des prostata-spezifischen antigens
CY2457B1 (en)	2005-06-03	Peptide immunogens for vaccination against and treatment of allergy.
Chaouat et al.	1980	Immunoactive products of mouse placenta: I. immuno-suppressive effects of crude and water soluble extracts
EP1015489A4 (en)	2001-02-14	DENDRITIC CELL RECEPTOR
ZA862539B (en)	1986-11-26	Ghrh antagonists ix
WO1999065517A3 (en)	2000-02-03	Therapeutic compositions that produce an immune response by altering the antigen
MX2022003100A (es)	2022-04-06	Un inmunoterapeutico para el tratamiento del cancer de prostata.
WO1997047271A3 (en)	1998-02-12	Cellular vaccines and immunotherapeutics and methods for their preparation
Gensler	1988	Enhancement of chemical carcinogenesis in mice by systemic effects of ultraviolet irradiation
Wang et al.	2020	A fentanyl vaccine constructed upon opsonizing antibodies specific for the Galα1–3Gal epitope
WO2002022659A3 (en)	2003-01-23	DISCRIMINATION BETWEEN GnRH-I AND GnRH-II
Ablin	1977	Hormonal epidemiology of prostatic cancer
WO2003103706A3 (en)	2004-02-19	IMMUNOGENIC COMPOSITIONS
EP1555316A3 (en)	2008-01-30	Antigen library immunization
Bansal et al.	1978	Effect of Embryonic Tissue Immunization on Chemically Induced Gastrointestinal Tumors in Rats. I. Can Embryonic Antigens Act as Rejection Antigens? 2
Price	2012	RW Baldwin1, VS Byers1, D. Hannant1, JA Jones1, MV Pimm1 and
Gallagher	1988	Lightning on the Links